Autologous Stem Cell Transplantation in Lymphoma

Seminars in Hematology

Volumn 44, Issue 4, 2007, Pages 234-245

  Schmitz, Norbert ^a   Buske, Christian ^b   Gisselbrecht, Christian ^c  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB Y 90; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RADIOISOTOPE; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LYMPHOBLASTOMA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; T CELL LYMPHOMA; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 35348999598     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.08.007     Document Type: Article

References (83)

1. Gratwohl A., Baldomero H., Frauendorfer K., Urbano-Ispizua A., Niederwieser D., et al., Joint Accreditation Committee of the International Society for Cellular Therapy ISCT. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: Focus on increasing use of unrelated donors. Bone Marrow Transplant 39 (2007) 71-87
2. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
3. Herold M., Haas A., Srock S., Neser S., Al-Ali K.H., Neubauer A., et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology study. J Clin Oncol 25 (2007) 1986-1992
4. Diehl V., Franklin J., Pfreundschuh M., Lathan B., Paulus U., Hasenclever D., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
5. Horning S.J., Hoppe R.T., Breslin S., Bartlett N.L., Brown B.W., and Rosenberg S.A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20 (2002) 630-637
6. Radford J.A., Rohatiner A.Z.S., Ryder W.D.J., et al. ChlVPP/EVA hybrid v the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 20 (2002) 2988-2994
7. Gobbi P.G., Cavalli C., Federico M., Bertoloni D., Di Prisco U.A., Rossi A., et al. Hodgkin's disease prognosis: a directly predictive equation. Lancet 1 (1988) 675-679
8. Straus D.J., Gaynor J.J., Myers J., Merke D.P., Caravelli J., Chapman D., et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8 (1990) 1173-1186
9. Proctor S.J., Taylor P., Donnan P., Boys R., Lennard A., and Prescott R.J. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer 27 (1991) 624-629
10. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (1998) 1506-1514
11. Hasenclever D., Schmitz N., and Diehl V. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease?. German Hodgkin's Lymphoma Study Group (GHSG). Leuk Lymphoma 15 suppl 1 (1995) 47-49
12. Carella A.M., Carlier P., Congiu A., Occhini D., Nati S., Santini G., et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 8 (1991) 99-103
13. Federico M., Bellei M., Brice P., Brugiatelli M., Nagler A., Gisselbrecht C., et al. High-dose therapy and autologous stem-cell transplantation v conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21 (2003) 2320-2325
14. Josting A., Franklin J., May M., Koch P., Beykirch M.K., Heinz J., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 20 (2002) 221-230
15. Lohri A., Barnett M., Fairey R.N., O'Reilly S.E., Phillips G.L., Reece D., et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77 (1991) 2292-2298
16. Brice P., Bastion Y., Divine M., Nedellec G., Ferrant A., Gabarre J., et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 78 (1996) 1293-1299
17. Lazarus H.M., Loberiza Jr. F.R., Zhang M.J., Armitage J.O., Ballen K.K., Bashey A., et al. Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27 (2001) 387-396
18. Josting A., Reiser M., Rueffer U., Salzberger B., Diehl V., and Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure?. J Clin Oncol 18 (2000) 332-339
19. Linch D.C., Winfield D., Goldstone A.H., Moir D., Hancock B., McMillan A., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341 (1993) 1051-1054
20. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A.M., Haenel M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359 (2002) 2065-2071
21. Schmitz N., Haverkamp H., Josting A., Carella A.M., Haenel M., Boissevain F., et al. Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Proc Am Soc Clin Oncol 23 (2005) 562s (abstr)
22. Moskowitz C.H., Kewalramani T., Nimer S.D., Gonzalez M., Zelenetz A.D., and Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124 (2004) 645-652
23. Sweetenham J.W., Carella A.M., Taghipour G., Cunningham D., Marcus R., Della Volpe A., et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17 (1999) 3101-3109
24. Lazarus H.M., Rowlings P.A., Zhang M.J., Vose J.M., Armitage J.O., Bierman P.J., et al. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17 (1999) 534-545
25. Andre M., Henry-Amar M., Pico J.L., Brice P., Blaise D., Kuentz M., et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 17 (1999) 222-229
26. Robinson SP, Sureda A, Canals C, Taghipour G, Russell N, Caballero D, et al: Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's disease: Identification of prognostic factors predicting outcome. Blood (submitted)
27. Kuruvilla J., Nagy T., Pintilie M., Tsang R., Keating A., and Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106 (2006) 353-360
28. Baetz T., Belch A., Couban S., Imrie K., Yau J., Myers R., et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14 (2003) 1762-1767
29. Moskowitz C.H., Nimer S.D., Zelenetz A.D., Trippett T., Hedrick E.E., Filippa D.A., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 97 (2001) 616-623
30. Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., and Kansu E. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: A salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 688-697
31. Spaepen K., Stroobants S., Dupont P., Vandenberghe P., Maertens J., Bormans G., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102 (2003) 53-59
32. Coiffier B. Monoclonal antibodies in the treatment of indolent lymphomas. Best Pract Res Clin Haematol 18 (2005) 69-80
33. Buske C., Weigert O., Dreyling M., Unterhalt M., and Hiddemann W. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 91 (2006) 104-112
34. Marcus R., Imrie K., Belch A., Cunningham D., Flores E., Catalano J., et al. CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
35. Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (2005) 3725-3732
36. Voso M.T., Martin S., Hohaus S., Abdallah A., Schlenk R.F., Ho A.D., et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 25 (2000) 957-964
37. Berglund A., Enblad G., Carlson K., Glimelius B., and Hagberg H. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 65 (2000) 17-22
38. Apostolidis J., Foran J.M., Johnson P.W., Norton A., Amess J., Matthews J., et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 17 (1999) 216-221
39. Lenz G., Dreyling M., Schiegnitz E., Forstpointner R., Wandt H., Freund M., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
40. Deconinck E., Foussard C., Milpied N., Bertrand P., Michenet P., Cornillet-LeFebvre P., et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood 105 (2005) 3817-3823
41. Sebban C., Mounier N., Brousse N., Belanger C., Brice P., Haioun C., et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108 (2006) 2540-2544
42. Brice P., Simon D., Bouabdallah R., Belanger C., Haioun C., Thieblemont C., et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11 (2000) 1585-1590
43. Freedman A.S., Neuberg D., Mauch P., Soiffer R.J., Anderson K.C., Fisher D.C., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94 (1999) 3325-3333
44. Cao T.M., Horning S., Negrin R.S., Hu W.W., Johnston L.J., Taylor T.L., et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. Biol Blood Marrow Transplant 7 (2001) 294-301
45. Vignot S., Mounier N., Larghero J., Brice P., Quero L., de Bazelaire C., et al. High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: A study using patients as their own controls. Cancer 109 (2007) 60-67
46. Schouten H.C., Qian W., Kvaloy S., Porcellini A., Hagberg H., Johnson H.E., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 21 (2003) 3918-3927
47. Cheson B.D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101 (2003) 391-398
48. Witzig T.E. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol 19 (2006) 655-668
49. Gopal A.K., Gooley T.A., Maloney D.G., Petersdorf S.H., Eary J.F., Rajendran J.G., et al. High-dose radioimmunotherapy v conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood 102 (2003) 2351-2357
50. Press O.W., Eary J.F., Gooley T., Gopal A.K., Liu S., Rajendran J.G., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96 (2000) 2934-2942
51. Vose J.M., Bierman P.J., Enke C., Hankins J., Bociek G., Lynch J.C., and Armitage J.O. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 461-467
52. Pfreundschuh M., Trumper L., Osterborg A., Pettengell R., Trneny M., Imrie K., et al. CHOP-like chemotherapy plus rituximab v CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7 (2006) 379-391
53. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
54. Haioun C., Lepage E., and Gisselbrecht C. Survival benefit of high dose therapy in poor risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A Groupe d'Etude des Lymphomse de l'Adulte study. J Clin Oncol 18 (2000) 3025-3030
55. Gianni A.M., Bregni M., and Siena S. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336 (1997) 1290-1296
56. Santini G., Salvagno L., and Leoni P. VACOP-B v VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Group. J Clin Oncol 16 (1998) 2796-2802
57. Milpied N., Deconinck E., and Gailllard F. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. N Engl J Med 350 (2004) 1287-1295
58. Betticher D.C., Martinelli G., Radford J.A., Kaufmann M., Dyer M.J., Kaiser U., et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: Results of the international randomized phase III trial (MISTRAL). Ann Oncol 17 (2006) 1546-1552
59. Kluin-Nelemans H.C., Zogonel V., and Anastopoulou A. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 93 (2001) 22-30
60. Kaiser U., Uebelacker I., and Abel U. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 20 (2002) 4413-4419
61. Glass B., Kloess M., and Bentz M. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107 (2006) 3058-3064
62. Mounier N., Gisselbrecht C., and Brière J. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 22 (2004) 2826-2834
63. Mounier N., Gisselbrecht C., and Briere J. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: A matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 15 (2004) 1790-1797
64. Greb A., Bohlius J., Trelle S., Schiefer D., De Souza C.A., Gisselbrecht C., et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma-Results of a comprehensive meta-analysis. Cancer Treat Rev 33 (2007) 338-346
65. Gisselbrecht C., Lepage E., and Molina T. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20 (2002) 2472-2479
66. Tarella C., Zanni M., and Di Nicolas M. High CR rate and prolonged EFS in aaIPI 2-3 diffuse large B-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen): Results of a prospective phase II multicenter study sponsored by GITIL (Gruppo Italiano Teraie Innovative nei Limfomi). Blood 106 (2005) 2068 (abstr)
67. Belhadj K., Fitoussi O., and Haioun C. Rituximab combined to ACVBP (R-ACVBP) as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first line. Preliminary results on 119 patients of a GELA phase II study. Blood 108 (2006) 3049 (abstr)
68. Glass B, Kloess M, Reiser M, Freund M, Truemper M, Metzner B. et al: Repeated high-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Leukemia (submitted)
69. Haioun C., Mounier N., and Emile J.F. Rituximab vs. observation after high dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma. Final analysis of the LNH98-B3 study GELA study. Blood 106 (2005) 677 (abstr)
70. Velasquez W.S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71 (1988) 117-122
71. Philip T., Guglielmi C., and Hagenbeek A. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
72. + NHL. A prospective randomised HOVON trial. Blood 108 (2006) 328 (abstr)
73. Kewalramani T., Zelenetz A.D., and Nimer S.D. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103 (2004) 3684-3688
74. 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
75. Dreger P., Rieger M., Seyfarth B., Hensel M., Kneba M., Ho A.D., et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: Effects on molecular response and clinical outcome. Haematologica 92 (2007) 42-49
76. De Souza C., Cardoso R.B., Simoes B., Maiolino A., Moraes A.A.J.C., Ruiz M.A., et al. Unselected high-risk IPI NHL presented a high early mortality rate in a prospective randomized study comparing conventional chemotherapy and high-dose escalation followed by autologous bone marrow transplantation. Blood 98 (2001) 5346
77. Intragumtornchai T., Prayoonwiwat W., and Numbenjapon T. CHOP v CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma. Clin Lymphoma 1 (2000) 219-225
78. Martelli M., Vignetti M., and Zinzani P.L. High-dose chemotherapy followed by autologous bone marrow transplantation v dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized italian multicenter study. J Clin Oncol 14 (1996) 534-542
79. Martelli M., Gherlinzoni F., and De Renzo A. Early autologous stem-cell transplantation v conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial. J Clin Oncol 21 (2003) 1255-1262
80. Verdonck L.F., van Putten W.L., and Hagenbeek A. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332 (1995) 1045-1051
81. Vitolo U., Liberati A.M., and Cabras M.G. High dose sequential chemotherapy with autologous transplantation v dose-dense chemotherapy megaCEOP as first line treatment in poor-prognosis diffuse large ell lymphoma: An "Intergruppo Italiano Linfomi" randomized trial. Haematologica 90 (2005) 793-801
82. Olivieri A., Santini G., and Patti C. Upfont high-dose sequential therapy (HDS) v VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: Long term results by the NHLCSG. Ann Oncol 16 (2005) 1941-1948
83. Rodriguez M.A., van Besien K., and Hagemeister F.B. Randomized comparison of frontline alternating chemotherapy (ATT) v brief induction followed by autologous stem cell transplantation (ASCT) for aggressive lymphomas. Blood 102 (2003) 11 (abstr. 1458)